1 Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med352, 987-996, doi:10.1056/NEJMoa043330 (2005).
2 Cancer Genome Atlas Research, N. et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med372, 2481-2498, doi:10.1056/NEJMoa1402121 (2015).
3 Bell, E. H. et al. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. J Clin Oncol38, 3407-3417, doi:10.1200/JCO.19.02983 (2020).
4 Karim, A. B. et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys52, 316-324, doi:10.1016/s0360-3016(01)02692-x (2002).
5 Baumert, B. G. et al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol17, 1521-1532, doi:10.1016/S1470-2045(16)30313-8 (2016).
6 Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med370, 699-708, doi:10.1056/NEJMoa1308573 (2014).
7 Brem, H. et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet345, 1008-1012, doi:10.1016/s0140-6736(95)90755-6 (1995).
8 Johnson, B. E. et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science343, 189-193, doi:10.1126/science.1239947 (2014).
9 Sonabend, A. M. et al. The transcriptional regulatory network of proneural glioma determines the genetic alterations selected during tumor progression. Cancer Res74, 1440-1451, doi:10.1158/0008-5472.CAN-13-2150 (2014).
10 Ohgaki, H. & Kleihues, P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol170, 1445-1453, doi:10.2353/ajpath.2007.070011 (2007).
11 Crespo, I. et al. Molecular and Genomic Alterations in Glioblastoma Multiforme. Am J Pathol185, 1820-1833, doi:10.1016/j.ajpath.2015.02.023 (2015).
12 Wang, S. I. et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res57, 4183-4186 (1997).
13 Yang, J. M. et al. Characterization of PTEN mutations in brain cancer reveals that pten mono-ubiquitination promotes protein stability and nuclear localization. Oncogene36, 3673-3685, doi:10.1038/onc.2016.493 (2017).
14 England, B., Huang, T. & Karsy, M. Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol34, 2063-2074, doi:10.1007/s13277-013-0871-3 (2013).
15 Cairncross, G. & Jenkins, R. Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J14, 352-357, doi:10.1097/PPO.0b013e31818d8178 (2008).
16 Eckel-Passow, J. E. et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med372, 2499-2508, doi:10.1056/NEJMoa1407279 (2015).
17 Smith, J. S. et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst93, 1246-1256, doi:10.1093/jnci/93.16.1246 (2001).
18 Trent, J. et al. Evidence for rearrangement, amplification, and expression of c-myc in a human glioblastoma. Proc Natl Acad Sci U S A83, 470-473, doi:10.1073/pnas.83.2.470 (1986).
19 Habib, N. et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. Nat Methods14, 955-958, doi:10.1038/nmeth.4407 (2017).
20 Buenrostro, J. D., Wu, B., Chang, H. Y. & Greenleaf, W. J. ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. Curr Protoc Mol Biol109, 21 29 21-21 29 29, doi:10.1002/0471142727.mb2129s109 (2015).
21 Laks, D. R. et al. Large-scale assessment of the gliomasphere model system. Neuro Oncol18, 1367-1378, doi:10.1093/neuonc/now045 (2016).
22 Rohle, D. et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science340, 626-630, doi:10.1126/science.1236062 (2013).
23 Khorasani, M., Shahbazi, S., Hosseinkhan, N. & Mahdian, R. Analysis of Differential Expression of microRNAs and Their Target Genes in Prostate Cancer: A Bioinformatics Study on Microarray Gene Expression Data. Int J Mol Cell Med8, 103-114, doi:10.22088/IJMCM.BUMS.8.2.103 (2019).
24 Saino, M., Maruyama, T., Sekiya, T., Kayama, T. & Murakami, Y. Inhibition of angiogenesis in human glioma cell lines by antisense RNA from the soluble guanylate cyclase genes, GUCY1A3 and GUCY1B3. Oncol Rep12, 47-52 (2004).
25 Bajaj, R. et al. IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion. Oncogene39, 5979-5994, doi:10.1038/s41388-020-01410-z (2020).
26 Yang, Y. F. et al. IMPAD1 functions as mitochondrial electron transport inhibitor that prevents ROS production and promotes lung cancer metastasis through the AMPK-Notch1-HEY1 pathway. Cancer Lett485, 27-37, doi:10.1016/j.canlet.2020.04.025 (2020).
27 Choi, C. H. et al. Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: expression of GRIA2 predicts better survival. Br J Cancer107, 91-99, doi:10.1038/bjc.2012.217 (2012).
28 Ishii, H. et al. FEZ1/LZTS1 gene at 8p22 suppresses cancer cell growth and regulates mitosis. Proc Natl Acad Sci U S A98, 10374-10379, doi:10.1073/pnas.181222898 (2001).
29 Lu, J., Cowperthwaite, M. C., Burnett, M. G. & Shpak, M. Molecular Predictors of Long-Term Survival in Glioblastoma Multiforme Patients. PLoS One11, e0154313, doi:10.1371/journal.pone.0154313 (2016).
30 Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell17, 98-110, doi:10.1016/j.ccr.2009.12.020 (2010).
31 Ceccarelli, M. et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell164, 550-563, doi:10.1016/j.cell.2015.12.028 (2016).
32 Noushmehr, H. et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell17, 510-522, doi:10.1016/j.ccr.2010.03.017 (2010).
33 Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science321, 1807-1812, doi:10.1126/science.1164382 (2008).
34 Chung, C. et al. Integrated Metabolic and Epigenomic Reprograming by H3K27M Mutations in Diffuse Intrinsic Pontine Gliomas. Cancer Cell38, 334-349 e339, doi:10.1016/j.ccell.2020.07.008 (2020).
35 Nagaraja, S. et al. Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State. Mol Cell76, 965-980 e912, doi:10.1016/j.molcel.2019.08.030 (2019).
36 Xu, W. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer Cell19, 17-30, doi:10.1016/j.ccr.2010.12.014 (2011).
37 Turcan, S. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature483, 479-483, doi:10.1038/nature10866 (2012).
38 Corces, M. R. et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. Nat Genet48, 1193-1203, doi:10.1038/ng.3646 (2016).
39 Stergachis, A. B. et al. Developmental fate and cellular maturity encoded in human regulatory DNA landscapes. Cell154, 888-903, doi:10.1016/j.cell.2013.07.020 (2013).
40 Corces, M. R. et al. The chromatin accessibility landscape of primary human cancers. Science362, doi:10.1126/science.aav1898 (2018).